Advertisement

Structure and Function in Recombinant HIV-1 gp120 and Speculation about the Disulfide Bonding in the gp120 Homologs of HIV-2 and SIV

  • Timothy Gregory
  • James Hoxie
  • Colin Watanabe
  • Michael Spellman
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 303)

Abstract

The envelope glyco-proteins of the primate immunodeficiency viruses (HIV-1, HIV-2 and SIV) have been the objects of intense study since their discovery. The major envelope glycoprotein (gp120 in HIV-1) is of particular interest because it mediates the attachment of the virus to susceptible cells via the CD4 molecule1,2, it contains most of the important epitopes for neutralization of the virus by antibodies3,4,5, it plays an important role in the process by which the viral and host cell membranes fuse and the viral capsid gains access to the cytoplasm6,7, and its sequence variability is central to the ability of the virus to adapt to and escape the protective immune response of the host organism8. Complete understanding of these processes requires an understanding of the molecular structure of gp120 in detail. Such structural information has proven to be difficult to obtain because of the large size of gp120 (approximately 480 amino acids), its high degree of glycosylation (approximately 50% by weight), the high degree of heterogeneity of the oligosaccharides on the molecule, and the scarcity of material available for analysis.

Keywords

Human Immunodeficiency Virus Human Immunodeficiency Virus Type Hypervariable Region High Mannose Envelope Glycoprotein Gp120 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. G. Dalgleish, P. C. L. Beverely, P. R. Clapham, D. H. Crawford, M. F. Greaves, and R. A. Weiss, The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus, Nature. 312:763 (1984).PubMedCrossRefGoogle Scholar
  2. 2.
    D. H. Smith, R. A. Byrne, S. A. Marsters, T. J. Gregory, J. E. Groopman, and D. J. Capon, Blocking of human immunodeficiency virus infectivity by a soluble, secreted form of the CD4 antigen, Science. 238:1704 (1987).PubMedCrossRefGoogle Scholar
  3. 3.
    K. Javaherian, A. J. Langlois, C. McDanal, K. L. Ross, L. I. Eckler, C. L. Jellis, A. T. Profy, J. R. Rusche, D. P. Bolognesi, S. D. Putney, and T. J. Matthews, Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein, Proc. Natl. Acad. Sci. USA. 86: 6768 (1989).PubMedCrossRefGoogle Scholar
  4. 4.
    P. W. Berman, T. J. Gregory, L. Riddle, G. R. Nakamura, M. A. Champe, J. P. Porter, F. M. Wurm, R. D. Hershberg, E. K. Cobb, and J. W. Eichberg, Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160, Nature. 345: 622 (1990).PubMedCrossRefGoogle Scholar
  5. 5.
    I. Berkower, G. E. Smith, C. Giri, and D. Murphy, Human immunodeficiency virus type 1, predominance of a group-specific neutralizing epitope that persists despite genetic variation, J. Exp. Med. 170: 1681 (1989).PubMedCrossRefGoogle Scholar
  6. 6.
    J. D. Lifson, M. B. Feinberg, G. R. Reyes, L. Rabins, B. Banapour, S. Chakrabati, B. Moss, F. Wong-Staal, K. S. Steimer, and E. G. Engleman, Induction of CD4-dependent cell fusion by the HTLV-III/LAV envelope glycoprotein, Nature. 323: 725 (1986).PubMedCrossRefGoogle Scholar
  7. 7.
    J. Sodroski, W. C. Goh, C. Rosen, K. Campbell, and W. A. Haseltine, Role of the HTLV-III/LAV envelope in syncitium formation and cytopathicity, Nature. 322:470 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    S. Modrow, B. H. Hahn, G. M. Shaw, R. C. Gallo, F. Wong-Staal, and H. Wolf, Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions, J. Virol. 61: 570 (1987).PubMedGoogle Scholar
  9. 9.
    L. A. Lasky, J. E. Groopman, C. W. Fennie, P. M. Benz, D. J. Capon, D. J. Dowbenko, G. R. Nakamura, W. M. Nunes, E. M. Renz, and P. W. Berman, Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein, Science. 237: 209 (1986).CrossRefGoogle Scholar
  10. 10.
    L. A. Lasky, G. Nakamura, D. H. Smith, C. Fennie, C. Shimasaki, E. Patzer, P. Berman, T. Gregory, and D. J. Capon, Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor, Cell. 50:975 (1987).PubMedCrossRefGoogle Scholar
  11. 11.
    C. K. Leonard, M. W. Spellman, L. Riddle, R. J. Harris, J. N. Thomas, and T. J. Gregory, Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells, J. Biol. Chem. 265: 10373 (1990).PubMedGoogle Scholar
  12. 12.
    D. C. Capon, S. M. Chamow, J. Mordenti, S. A. Marsters, T. Gregory, H. Mitsuya, R. A. Byrn, C. Lucas, F. M. Wurm, J. E. Groopman, S. Broder, and D. H. Smith, Designing CD4 immunoadhesins for AIDS therapy,Nature. 337: 525 (1989).PubMedCrossRefGoogle Scholar
  13. 13.
    M. Kowalski, J. Potz, L. Basiripour, T. Dorfman, W. C. Goh, E. Terwilliger, A. Dayton, C. Rosen, W. Haseltine, and J. Sodroski, Functional regions of the envelope glycoprotein og human immunodeficiency virus type 1, Science. 237: 1351 (1987).PubMedCrossRefGoogle Scholar
  14. 14.
    A. Cordonnier, L. Montagnier, and M. Emerman, Single amino acid changes in HIV envelope affect viral tropism and receptor binding, Nature. 340: 571 (1989).PubMedCrossRefGoogle Scholar
  15. 15.
    A. Nygren, T. Bergman, T. Matthews, H. Jornvall, and H. Wigzell, 95 and 25 kDa fragments of the human immunodeficiency virus envelope glycoprotein gp120 bind to the CD4 receptor,Proc.Natl. Acad. Sci. USA. 85: 6543 (1988).PubMedCrossRefGoogle Scholar
  16. 16.
    G. Meyers, A. Rabson, S. Josephs, T. Smith, J. Berzofsky, and F. Wong-Staal, eds., “Human Retroviruses and AIDS, LA-UR, 89–743, Los Alamos National Laboratory, Los Alamos (1989).Google Scholar
  17. 17.
    H. Geyer, C. Holschbach, G. Hunsmann, and J. Schneider, Carbohydrates of human immunodeficiency virus, J. Biol. Chem. 263: 11760 (1988).PubMedGoogle Scholar
  18. 18.
    T. Mizuochi, T. J. Matthews, M. Kato, J. Hamako, K. Titani, J. Solomon, and T. Feizi, Diversity of oligosaccharide structures on the envelope glycoprotein gp120 of human immunodeficiency virus 1 from the lymphoblastoid cell line H9, J. Biol. Chem. 265: 8519 (1990).PubMedGoogle Scholar
  19. 19.
    T. Mizuochi, M. W. Spellman, M. Larkin, J. Solomon, L. J. Basa, and T. Feizi, Carbohydrate structures of the human immunodeficiency virus (HIV) recombinant envelope glycoprotein gp120 produced in Chinese hamster ovary cells, Biochem. J. 254: 599 (1988).PubMedGoogle Scholar
  20. 20.
    R. J. Harris, S. M. Chamow, T. J. Gregory, and M. W. Spellman, Characterization of a soluble form of human CD4, Eur, J,Biochem. 188:291 (1990).CrossRefGoogle Scholar
  21. 21.
    P. R. Clapham, J. N. Weber, D. Whitby, K. Mcintosh, A. G. Dalgleish, P. J. Maddon, K. C. Deen, R. W. Sweet, and R. A. Weiss, Soluble CD4 blocks the infectivity of diverse strains of HIV and SIV for T cells and moncytes but not for brain and muscle cells, Nature. 337: 368 (1989).PubMedCrossRefGoogle Scholar
  22. 22.
    R. A. Byrn, I. Sekigawa, S. M. Chamow, J. S. Johnson, T. J. Gregory, D. J. Capon, and J. E. Groopman, Characterization of in vitro inhibition of human immunodeficiency virus by purified CD4, J. Virol. 63: 4370 (1989).PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Timothy Gregory
    • 1
  • James Hoxie
    • 4
  • Colin Watanabe
    • 2
  • Michael Spellman
    • 3
  1. 1.Depts. of Process SciencesGenentech, Inc.San FranciscoUSA
  2. 2.Depts. of Scientific ComputingGenentech, Inc.San FranciscoUSA
  3. 3.Depts. of Medicinal and Analytical ChemistryGenentech, Inc.San FranciscoUSA
  4. 4.Hematology-Oncology SectionHospital of the University of PennsylvaniaPhiladelphiaUSA

Personalised recommendations